CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 65 enrolled
Drug / intervention
LT3001 drug product +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04809818
NCT04809818Phase 1Completed

Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of LT3001 Drug Product and Drug-Drug Interaction in Healthy Adult Subjects

Lumosa Therapeutics Co., Ltd.·interventional·Posted Mar 22, 2021·Updated Mar 2, 2026

In Brief

A Phase 1 clinical trial evaluating LT3001 drug product, Placebo, and 4 other interventions for Acute Ischemic Stroke. Completed, enrolled 65 participants across 1 site.

Detailed Summary

This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedMar 22, 2021
Enrollment StartMar 21, 2021
Primary CompletionAug 5, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.3 years ago

Interventions

LT3001 drug productdrug

Multiple doses of LT3001 drug product administered by intravenous infusion

Placebodrug

Multiple doses of Placebo administered by intravenous infusion

Aspirindrug

Loading and maintenance doses of Aspirin administered by oral

Clopidogreldrug

Loading and maintenance doses of Clopidogrel administered by oral

Apixabandrug

Multiple doses of Apixaban administered by oral

Dabigatrandrug

Multiple doses of Dabigatran administered by oral